Lumexa Imaging (NASDAQ:LMRI - Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.860-0.900 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Wall Street Analyst Weigh In
LMRI has been the topic of a number of research analyst reports. Raymond James Financial set a $17.00 price target on Lumexa Imaging in a report on Monday, September 28th. UBS Group reaffirmed a "strong-buy" rating on shares of Lumexa Imaging in a report on Monday, September 28th. Weiss Ratings reiterated a "sell (d)" rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Lumexa Imaging in a report on Thursday, August 13th. Finally, Wall Street Zen raised shares of Lumexa Imaging from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $16.40.
Read Our Latest Research Report on Lumexa Imaging
Lumexa Imaging Stock Performance
LMRI stock opened at $16.27 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. The business's fifty day simple moving average is $11.24 and its two-hundred day simple moving average is $11.07. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45. The firm has a market cap of $1.56 billion and a price-to-earnings ratio of -33.32.
Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.19. The firm had revenue of $271.97 million during the quarter. Analysts predict that Lumexa Imaging will post 0.25 earnings per share for the current year.
Key Headlines Impacting Lumexa Imaging
Here are the key news stories impacting Lumexa Imaging this week:
- Positive Sentiment: Lumexa reported EPS of $0.26, beating the $0.07 consensus estimate cited in one report; the company also issued guidance. Article: Lumexa tops Q3 EPS and offers guidance
- Positive Sentiment: Gross profit grew 16.9% year over year to $46.4 million, and operating cash flow rose 193.5% to $34.8 million—signs of improved gross profitability and cash generation. Article: Lumexa Q3 earnings details
- Neutral Sentiment: The earnings call transcript and results release provide additional context, but the supplied reports do not detail the company’s guidance figures or call commentary. Article: Lumexa Q3 2026 earnings call transcript
- Negative Sentiment: Revenue was $272.0 million, up 5% year over year but below the $275.3 million estimate. A separate data analysis reports diluted EPS of $0.07 versus its $0.19 estimate, while operating profit fell 7.3% to $28.1 million. These figures may use a different EPS measure from the $0.26 headline figure. Article: Lumexa Q3 earnings details
About Lumexa Imaging
(
Get Free Report)
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lumexa Imaging, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lumexa Imaging wasn't on the list.
While Lumexa Imaging currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
